MedTrace Logo

CX717 in the Treatment of Adult ADHD

NCT03375021 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2017-12-15

No results posted yet for this study

Summary

A Randomized, Double-Blind, Two-Period Crossover Study to Assess the Efficacy And Safety of the Ampakine® Compound, CX717, versus Placebo in Adults with Attention-Deficit Hyperactivity Disorder

Conditions

  • Attention Deficit Hyperactivity Disorder

Interventions

DRUG

CX717 200 mg

CX717 200 mg capsules BID

DRUG

CX717 800 mg

CX717 4 X 200 mg capsules BID

DRUG

Placebo

Placebo 200 mg or 800 mg capsules BID

Sponsors & Collaborators

  • RespireRx

    lead INDUSTRY

Principal Investigators

  • Len Adler, MD · NYU School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-19
Primary Completion
2006-01-10
Completion
2006-01-10
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03375021 on ClinicalTrials.gov